LENZ Therapeutics, Inc. Overview
Pro stress-test →LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmologic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia. The company received FDA approval of VIZZ in July 2025 and initiated a commercial launch in October 2025. The company targets the multi-billion dollar presbyopia market affecting ~130 million Americans over 45 seeking alternatives to reading glasses.
Strategic Profile
Pro stress-test →LENZ is promoting VIZZ to adults living with age-related blurry near vision through direct-to-consumer initiatives, such as the "Make it VIZZable" campaign featuring Sarah Jessica Parker as brand ambassador. The company has international expansion plans including exclusive commercialization partnerships for VIZZ in the Middle East and Southeast Asia. Early commercial traction shows strong adoption with physician and patient interest despite recent FDA safety reporting creating near-term volatility.
Competitive Landscape
Pro stress-test →LENZ competes against companies including EyePoint Pharmaceuticals, Opus Genetics, and Kodiak Sciences in the ophthalmology space. As the first FDA-approved aceclidine-based eye drop, LENZ has first-mover advantage in presbyopia treatment, but faces competition from established ophthalmology players and alternative treatments like reading glasses and contacts.
Industry Context
LENZ Therapeutics, Inc. operates in Biopharmaceutical / Ophthalmology.
Key facts
Founded: 2013 · Headquarters: Solana Beach, California · Employees: 42 · Revenue: $17.5M · Market cap: $423M